Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. director Steven Gannon reported selling 10,000 Common Shares on August 11, 2026 in an open market or private transaction. The shares were sold at a weighted-average price of $64.055 across multiple trades priced between $64.0517 and $64.078 per share. Following this sale, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider GANNON STEVEN

Role Director

Sold 10,000 shs ($641K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1	10,000	$64.055	$641K

Holdings After Transaction: Common Shares — 1,870 shares (Direct)

Footnotes (1)

1. F1. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Key Figures

Shares sold: 10,000 shares Weighted-average sale price: $64.055 per share Price range of sales: $64.0517 to $64.078 per share +2 more

5 metrics

Shares sold 10,000 shares Common Shares sold by director Steven Gannon on August 11, 2026

Weighted-average sale price $64.055 per share Aggregate weighted-average price for the 10,000 shares sold

Price range of sales $64.0517 to $64.078 per share Range of individual transaction prices for the sold shares

Shares held after transaction 1,870 shares Total Common Shares directly owned by Steven Gannon after the sale

Net shares sold (Form 4 summary) 10,000 shares Net sell shares according to the transaction summary

Key Terms

weighted-average price, open market or private transaction, SEC staff

3 terms

weighted-average price financial

"reflect the aggregate number and weighted-average price, respectively, of shares"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open market or private transaction financial

"transaction code description: Sale in open market or private transaction"

SEC staff regulatory

"provide to the issuer, any security holder of the issuer, or the SEC staff"

FAQ

What insider transaction did Xenon Pharmaceuticals (XENE) report?

Xenon Pharmaceuticals reported that director Steven Gannon sold 10,000 Common Shares on August 11, 2026. The transaction was reported as a sale in an open market or private transaction, leaving him with 1,870 shares held directly afterward.

How many Xenon Pharmaceuticals (XENE) shares did Steven Gannon sell and at what price?

Steven Gannon sold 10,000 Common Shares of Xenon Pharmaceuticals at a weighted-average price of $64.055 per share. The footnote states the individual trades occurred in a price range from $64.0517 to $64.078 per share.

What is Steven Gannon’s remaining Xenon Pharmaceuticals (XENE) shareholding after this Form 4?

After the reported sale, Steven Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc. This post-transaction holding is disclosed in the Form 4 as the total shares following the transaction in the non-derivative securities table.

Were the Xenon Pharmaceuticals (XENE) insider sales executed as multiple trades?

Yes. The filing notes the 10,000 shares were sold in multiple transactions with prices ranging from $64.0517 to $64.078. The reported $64.055 figure represents a weighted-average price across these individual trades.

Was the Xenon Pharmaceuticals (XENE) director’s sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and the footnote does not reference any trading plan. Based on this disclosure, the reported 10,000-share sale is not identified as being executed under a Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:33 PM Accepted by SEC EDGAR 08/13/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GANNON STEVEN

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY V5G 4W8

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/11/2026		S		10,000	D	$64.055(1)	1,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

	/s/ Nathaniel Adams, Attorney-in-fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)